ArticleNeuropsychopharmacology reports2025
Guideline for pharmacological treatment of schizophrenia 2022.
Article in Neuropsychopharmacology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Nationwide expansion of the EGUIDE project in Japan: A nine-year overview.PCN reports : psychiatry and clinical neurosciences · 2026Article
- Pharmacological treatment of schizophrenia: Japanese Expert Consensus 2025.Schizophrenia (Heidelberg, Germany) · 2026Article
- The introduction of measurement-based care for patients with schizophrenia may improve psychiatric symptoms and guideline adherence rate.The international journal of neuropsychopharmacology · 2026Article
- Changes in White Blood Cell and Neutrophil Counts in Patients With Schizophrenia Treated With Lithium Carbonate, Adenine, and Ninjin-Yoei-To: A Preliminary Study.Neuropsychopharmacology reports · 2026Article
- Article
- Clozapine-Associated Neutropenia among People on Clozapine in Japan: A Nationally Representative Retrospective Cohort Study.Schizophrenia bulletin · 2026Article
- Distress as a bridge to suicidality in schizophrenia spectrum disorders: a network-based intervention simulation study.Research square · 2026Article
- Treatment continuation and factors associated with discontinuation with 3-month paliperidone palmitate in patients with schizophrenia: aFrontiers in psychiatry · 2026Article
- Seizures associated with clozapine augmentation by other antipsychotics: a pharmacovigilance-pharmacodynamic analysis using VigiBase.Therapeutic advances in psychopharmacology · 2026Article
- Physical Therapies and Neuromodulation for Treatment-Resistant Schizophrenia: A Review of Potential Mechanisms, Efficacy, and Safety.Neuropsychiatric disease and treatment · 2026Review
- Awareness and management of cognitive impairment associated with schizophrenia in psychiatrists and patients: Results from a cross-sectional survey.Schizophrenia research. Cognition · 2025Article
- Factors associated with treatment failure after discharge in inpatients with schizophrenia spectrum disorders: A retrospective observational study.PCN reports : psychiatry and clinical neurosciences · 2025Article
- Guideline for pharmacological treatment of schizophrenia 2022.Neuropsychopharmacology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.